A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Trial details
- Registry ID
- NCT00750698
- Phase
- Phase 2
The FDA approved Erlotinib (Tarceva) on 18 Nov 2004.
Drug identity checked against registry records
Also recorded as Tarceva
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibNCT00750698 | Syndax Pharmaceuticals | Phase 2 | Terminated | 2010-05Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2004-11-18Day | Erlotinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021743", "applicant_as_listed_by_fda": "OSI PHARMS", "brand_names": ["TARCEVA"], "active_ingredients": ["ERLOTINIB HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20041118", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |